MediTest
Submitted by Jim K on Tue, 2006-01-17 20:11

David Wheldon offered this citation as another good reason to use alpha-lipoic acid as a supplement on the protocols here. This study notes it's anti-inflammatory effect through T-cell inhibition. Although this study is orienting from the autoimmune model of MS, David notes " I read this as positive, if you are taking antibiotics. While killing the organisms you want as little inflammation as possible."Alpha lipoic acid inhibits human T-cell migration: implications for multiple sclerosis.Marracci GH, McKeon GP, Marquardt WE, Winter RW, Riscoe MK, Bourdette DN.Portland Veterans Affairs Medical Center, Portland, Oregon, USA.We have demonstrated previously the ability of the antioxidant alpha lipoic acid (ALA) to suppress and treat a model of multiple sclerosis (MS), relapsing experimental autoimmune encephalomyelitis (EAE). We describe the effects of ALA and its reduced form, dihydrolipoic acid (DHLA), on the transmigration of human Jurkat T cells across a fibronectin barrier in a transwell system. ALA and DHLA inhibited migration of Jurkat cells in a dose-dependent fashion by 16-75%. ALA and DHLA reduced matrix metalloproteinase-9 (MMP-9) activity by 18-90% in Jurkat cell supernatants. GM6001, a synthetic inhibitor of MMP, reduced Jurkat cell migration, but not as effectively as ALA and DHLA did. Both ALA and DHLA downmodulated the surface expression of the alpha4beta1 integrin (very late activation-4 antigen; VLA-4), which binds fibronectin and its endothelial cell ligand vascular cell adhesion molecule-1 (VCAM-1). Moreover, ALA, but not DHLA, reduced MMP-9-specific mRNA and extracellular MMP-9 from Jurkat cells and their culture supernatants as detected by relative reverse transcriptase-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA), respectively. ALA and DHLA inhibited Jurkat cell migration and have different mechanisms for inhibiting MMP-9 activity. These data, coupled with its ability to treat relapsing EAE, suggest that ALA warrants investigation as a therapy for MS. Copyright 2004 Wiley-Liss, Inc.

Comments

This is a wonderful 2006 post.  It is now 2009. 

  • CAP(TiniOnly): 06/07-02/09 for CFS
  • MethylationProtocolSupplements: Started08/08
  • Intermtnt CAP: 02/09-02/10
  • Full MethylProtocol & LDN 02/09
  • Off CAP: 02/10, cont LDN & MethlyProtocol support